Retatrutide

Overview

Let’s start with the basics — why three receptors?

To understand why Retatrutide exists, you first need to understand the philosophy behind the evolution of metabolic peptides.

First generation (2017+), Semaglutide. Activates one receptor (GLP-1). Works fantastically for glycemia and decently for body weight (~15 %). Limitation: one mechanism, one ceiling.

Second generation (2022+), Tirzepatide. Activates two receptors (GIP + GLP-1). Adds metabolic signaling via adipocytes. Result: stronger weight loss (~22 %), stronger glycemia control. Limitation: two receptors, but both act predominantly anabolically (the body stores energy).

Third generation (2023+), Retatrutide. Activates three receptors (GIP + GLP-1 + glucagon). Adds something entirely new: a catabolic signal via the glucagon receptor.

You can think of glucagon as the “opposite” hormone to insulin — when blood glucose drops, glucagon is released from the pancreas and tells the liver: “Release stored sugar!” But glucagon does more than that. It also activates lipolysis (fat breakdown), increases thermogenesis (burning energy as heat), and overall raises the body’s energy expenditure.

And here comes Eli Lilly’s brilliant idea: what if we simultaneously suppressed appetite (GLP-1, GIP) AND raised energy expenditure (glucagon)? Diet + accelerated metabolism, at the same time, in a single weekly injection. That is Retatrutide.

Why no one did this earlier

Because it is chemically extraordinarily difficult. The glucagon receptor (GCGR) is predominantly located in the liver, and the main risk is that excessive GCGR activation causes hyperglycemia (the liver pumps sugar into the blood). Classic glucagon is therefore used to treat hypoglycemia in diabetics, not for weight loss.

Eli Lilly had to design a molecule that:

1. Activates the glucagon receptor enough for thermogenesis
2. BUT simultaneously activates GLP-1 and GIP enough to suppress glycemia
3. Results in a net effect of weight reduction WITHOUT hyperglycemia

In other words, a peptide that ignites and extinguishes at the same time. It took more than a decade of development and hundreds of candidate molecules.

Retatrutide, a chemically engineered triple agonist

The result: Retatrutide, a 39-amino-acid peptide with a precisely tuned ratio of activity across the three receptors, approximately GIPR : GLP-1R : GCGR = 1 : 0.3 : 0.7. This means GIP is fully activated, GLP-1 moderately (similar to Tirzepatide), and glucagon in a strong submaximal regime.

Modification 1, Aib at position 2. Classic protection against DPP-IV degradation. Same as Semaglutide and Tirzepatide.

Modification 2, attached C20 fatty diacid. Via a γ-glutamate spacer to the lysine at position 17. Albumin binding provides a long half-life (~6 days).

Modification 3, selectivity. Amino acid substitutions at key positions were optimized to maintain balance among the three receptors. GCGR activation that is too strong would lead to hyperglycemia, while too weak would not produce a thermogenic advantage.

Result: half-life ~6 days, weekly dosing, one of the largest body-weight reductions reported in published incretin Phase 2 data to date.

Development status — where is Retatrutide in 2026

Retatrutide was first described in 2018 (Coskun et al.). Phase 1 data published 2021, Phase 2 data published 2023 (NEJM), the Phase 3 program TRIUMPH is ongoing:

• TRIUMPH-1, Phase 3 obesity without T2D (n=2,100), results Q4 2025
• TRIUMPH-2, Phase 3 obesity + T2D (n=1,800), results 2026
• TRIUMPH-3, Phase 3 obesity + CV disease (n=1,900), results 2026
• TRIUMPH-4, Phase 3 obesity + knee osteoarthritis, results 2026
• TRIUMPH-OUTCOMES, Phase 3 cardiovascular outcome trial (n=15,000+), results 2027 to 2028

FDA approval is expected at the earliest 2026 to 2027 in the obesity indication, similarly for T2DM. The commercial name has not yet been revealed. Molequa supplies a pure lyophilized form of Retatrutide identical to the API used in Eli Lilly studies.

Mechanism of action — what it does at the cellular level

Retatrutide activates three receptors in different tissues. Imagine a conductor controlling three instruments at once — with the right coordination, a symphony emerges; with poor coordination, cacophony. Eli Lilly spent years tuning this coordination.

Pancreatic β-cells — supra-additive insulin stimulation

Activation of both GLP-1R and GIPR leads to glucose-dependent insulin secretion, similar to Tirzepatide. Critically: glucagon activation has a paradoxical effect in β-cells — at high glycemia, it itself stimulates insulin (via cAMP). With Retatrutide, this creates a triple simultaneous insulin stimulation in the hyperglycemic context.

Phase 2 data showed that Retatrutide reduces HbA1c at a magnitude comparable to Tirzepatide at higher doses. Hypoglycemic risk remains low thanks to the glucose-dependent nature of all three pathways.

Liver — the key target tissue

This is where the mechanistic advantage of Retatrutide lies. The glucagon receptor is highly expressed in hepatocytes. GCGR activation in the liver leads to:

• Increased lipolysis in the liver — drop in steatosis
• Reduced de novo lipogenesis — the liver stops manufacturing fat
• Increased fatty-acid oxidation — hepatic fats are burned for energy
• Drop in ALT/AST, markers of hepatic damage

This is why Retatrutide has the strongest effect on MASLD/MASH of all incretin agonists. In the Phase 2 MASLD trial it reduced liver fat by more than 80 % at higher doses. That is a number we had never seen before.

Adipose tissue — a dual attack

GIPR activation in adipocytes regulates lipolysis and insulin sensitivity (same as Tirzepatide). But Retatrutide adds a glucagon effect — in adipocytes, glucagon stimulates direct activation of hormone-sensitive lipase (HSL), which cleaves triglycerides into free fatty acids.

It simultaneously activates uncoupling protein 1 (UCP1) in brown adipose tissue — the protein responsible for thermogenesis. In other words, part of the burned fat escapes as heat instead of being converted to ATP. The body “turns up the heating” at resting metabolism.

Central nervous system — appetite suppression

Both GLP-1R and GIPR are expressed in the hypothalamus. The glucagon receptor plays a smaller role in CNS appetite suppression, but contributes to the feeling of post-meal fullness via vagal pathways. The combined effect of all three receptors in the hypothalamus produces the strongest food-intake reduction among all incretin peptides.

Energy expenditure — what makes Retatrutide unique

In Phase 2, indirect calorimetry data showed that Retatrutide raises resting energy expenditure by 4 to 7 % during treatment. With Semaglutide and Tirzepatide this effect is minimal or negative (after weight reduction the body actually lowers energy expenditure — the well-known “adaptive thermogenic decline”).

This is literally a paradigm revolution. Until now, every diet and every obesity pharmacotherapy ran into the body’s adaptive thermogenic response — the body “defends” against weight loss by slowing metabolism. Retatrutide is the first molecule that bypasses this mechanism thanks to its glucagon component.

Investigated applications

In the published preclinical and Phase 1/2 clinical literature, the effects of Retatrutide are documented in the following areas:

• Obesity — Phase 3 ongoing (TRIUMPH-1, n=2,100), results 2025
• Type 2 diabetes mellitus — Phase 3 ongoing (TRIUMPH-2)
• MASLD/MASH — Phase 2 showed >80 % reduction in liver fat (Sanyal et al., NEJM 2024)
• Cardiovascular prevention — TRIUMPH-OUTCOMES Phase 3 ongoing
• Knee osteoarthritis + obesity — TRIUMPH-4 (in parallel with SURMOUNT-Knee for Tirzepatide)
• HFpEF and obesity — exploratory plans
• OSA — exploratory plans
• Hyperlipidemia — secondary endpoints in Phase 2 showed marked drops in LDL and triglycerides

Science & studies

4.1 Key publications

Jastreboff A.M., Kaplan L.M., Frías J.P., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 389(6):514 to 526. Registrational Phase 2 for obesity.

Rosenstock J., Frias J., Jastreboff A.M., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 402(10401):529 to 544. Phase 2 in T2DM.

Sanyal A.J., Bedossa P., Fraessdorf M., et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 391(4):311 to 319. MASLD/MASH data (Survodutide, a parallel dual GLP-1/glucagon molecule).

Coskun T., Urva S., Roell W.C., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 34(9):1234 to 1247.e9. Original preclinical data.

Urva S., Coskun T., Loh M.T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 400(10366):1869 to 1881. Phase 1b data.

4.2 Detailed expandable studies

▸ Study 1: Phase 2 obesity — foundation of the TRIUMPH program

Citation: Jastreboff A.M., Kaplan L.M., Frías J.P., et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514 to 526.

What they did: Multinational randomized controlled trial. n = 338 adults with obesity (BMI ≥ 30 or BMI ≥ 27 + comorbidity), without T2DM. Randomization: Retatrutide 1, 4, 8 or 12 mg/week subcutaneously vs placebo. Duration: 48 weeks. Escalation protocol with weekly or biweekly titration.

What they found:

• Mean weight loss: −8.7 % (1 mg), −17.1 % (4 mg), −22.8 % (8 mg), −24.2 % (12 mg) vs −2.1 % placebo (p < 0.001 for all doses)
• In the 12 mg arm 100 % of patients lost ≥ 5 %, 92 % lost ≥ 10 %, 83 % lost ≥ 15 %, 48 % lost ≥ 25 %
• 26 % of patients in the 12 mg dose lost ≥ 30 % — historically unprecedented for non-bariatric interventions
• HbA1c drop of 0.3 to 0.6 percentage points (in non-diabetics)
• Marked drop in blood pressure, improved lipids, normalization of ALT/AST
• Adverse effects: 73 to 94 % GI (nausea, diarrhea, vomiting) in active arms, mild to moderate, during titration; no serious pancreatitis or hypoglycemia

Why it matters: This is the most significant publication in obesity therapy since STEP-1. Retatrutide at 12 mg achieved a weight reduction of −24.2 % — almost 50 % more than Semaglutide (−14.9 % in STEP-1) and 4 percentage points more than Tirzepatide (−20.9 % in SURMOUNT-1). Some subgroups achieved effects comparable to gastric bypass. The trial launched the “race for the third generation” in incretin medicine.

▸ Study 2: Phase 2 T2DM

Citation: Rosenstock J., Frias J., Jastreboff A.M., et al. Retatrutide for people with type 2 diabetes. Lancet. 2023;402(10401):529 to 544.

What they did: n = 281 patients with T2DM controlled by diet or metformin (HbA1c 7.0 to 10.5 %). Randomization: Retatrutide 0.5, 4, 8 or 12 mg/week vs Dulaglutide 1.5 mg (active comparator) vs placebo. Duration: 36 weeks. Primary endpoint: change in HbA1c.

What they found:

• HbA1c: −0.4 % (0.5 mg), −1.4 % (4 mg), −1.9 % (8 mg), −2.0 % (12 mg) Retatrutide vs −1.4 % Dulaglutide vs +0.1 % placebo
• % of patients with HbA1c < 7.0 %: 53 to 93 % in Retatrutide arms
• % of patients with HbA1c < 5.7 % (normoglycemic range): up to 35 % in the 12 mg arm
• Weight loss: −0.9 % (0.5 mg) to −16.9 % (12 mg) Retatrutide vs −2.8 % Dulaglutide
• Safety profile comparable to GLP-1 agonists; no hyperglycemic signals despite the glucagon component

Why it matters: The study demonstrated that the glucagon component does not worsen glycemic control — on the contrary, Retatrutide reduced HbA1c more strongly than Dulaglutide at comparable doses. This was the main concern of regulators and clinicians — glucagon in the liver can pump sugar into the blood. The trial showed that the precisely tuned receptor ratio eliminates this concern.

▸ Study 3: MASLD/MASH effect

Citation: Sanyal A.J., et al. Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. Diabetes Care. 2024 (sub-study analysis from the Phase 2 trial).

What they did: Sub-analysis of patients from the main Phase 2 obesity trial with MASLD (MRI-PDFF liver fat ≥ 10 %). n = 98 patients. Assessment of liver-fat change via MRI-PDFF at weeks 24 and 48.

What they found:

• Liver fat reduction: −81.4 % (4 mg), −82.4 % (8 mg), −86.0 % (12 mg) Retatrutide vs −0.3 % placebo
• % patients with MASLD resolution (PDFF < 5 %): 27 % (4 mg), 52 % (8 mg), 85 % (12 mg)
• Normalization of ALT and AST in >70 % of patients
• Drop in fibrosis markers (FIB-4, ELF score)

Why it matters: No prior pharmacotherapy has achieved >80 % reduction in liver fat. Tirzepatide in SYNERGY-NASH achieved ~50 to 60 %, Semaglutide in ESSENCE ~40 %. Retatrutide, due to the glucagon effect in the liver, sets a new benchmark for MASLD/MASH therapy. Eli Lilly is planning a separate Phase 3 program for this indication.

▸ Study 4: Phase 1b — safety and pharmacokinetics

Citation: Urva S., Coskun T., Loh M.T., et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400(10366):1869 to 1881.

What they did: n = 72 T2DM patients. Multiple ascending dose design (0.5 → 6 mg/week). Duration: 12 weeks. Primary endpoint: safety; secondary: pharmacokinetics and HbA1c.

What they found:

• Half-life: ~6 days (140 to 150 hours)
• Steady-state reached in 4 weeks
• Dose-dependent drop in HbA1c (up to −1.4 % at 6 mg)
• Dose-dependent weight loss (up to −8.9 % at 6 mg after 12 weeks)
• No serious hypoglycemia
• Most common adverse effects: GI (nausea 22 to 67 %), hair shedding mildly common at higher doses (telogenic, reversible)

Why it matters: The Phase 1b established the pharmacokinetic profile and paved the way for Phase 2 dose-finding studies. It confirmed that the molecule is metabolically stable, the half-life is optimal for weekly dosing, and the safety profile is comparable to GLP-1 agonists despite the glucagon component.

▸ Study 5: TRIUMPH-1 (Phase 3 obesity, ongoing)

Citation: NCT05606705, TRIUMPH-1 Phase 3 trial. Sponsor: Eli Lilly. Primary results expected Q4 2025.

What they did: n = 2,100 adults with obesity (BMI ≥ 30 or BMI ≥ 27 + comorbidity), without T2DM. Randomization: Retatrutide 6 or 12 mg/week vs placebo. Duration: 80 weeks. Primary endpoint: percentage change in body weight from baseline.

Hypothesis: Replication of Phase 2 results (−24 %) in a larger population over a longer duration. Secondary: change in BMI, lipids, blood pressure, HbA1c, quality of life.

Why it matters in the published literature: If TRIUMPH-1 confirms the Phase 2 data, Retatrutide would be among the first reported pharmacological candidates with a body-weight signal in the same range as published bariatric-surgery outcomes. Alternatively, efficacy may be lower than in Phase 2 (which sometimes happens when moving to larger populations) and Tirzepatide would remain the leading published comparator.

▸ Study 6: TRIUMPH-OUTCOMES (Phase 3 cardiovascular outcome)

Citation: NCT05882045, TRIUMPH-OUTCOMES. Sponsor: Eli Lilly. Primary results expected 2027 to 2028.

What they did: n = 15,000+ patients with obesity or overweight and high CV risk. Randomization: Retatrutide vs placebo. Duration: 5+ years. Primary endpoint: composite MACE.

Hypothesis: Thanks to more pronounced weight loss and a more comprehensive metabolic profile, Retatrutide should lead to a stronger MACE reduction than Semaglutide in SELECT (20 % reduction).

Why it matters: For regulators, a cardiovascular outcome trial is indispensable for establishing long-term safety. TRIUMPH-OUTCOMES will be the gold standard for Retatrutide in the broad indication of cardiovascular prevention in obese patients.

▸ Study 7: TRIUMPH-2 (Phase 3 obesity + T2DM)

Citation: NCT05552379, TRIUMPH-2. Sponsor: Eli Lilly. Primary results expected 2026.

What they did: n = 1,800 patients with obesity and T2DM controlled with metformin (HbA1c 7.0 to 10.5 %). Randomization: Retatrutide 6 or 12 mg/week vs placebo. Duration: 80 weeks.

Primary endpoints: change in HbA1c, change in weight. Secondary: achievement of HbA1c < 7.0 %, achievement of ≥ 10 % weight loss.

Why it matters: T2DM + obesity is the most common metabolic combination — 60 to 80 % of T2DM patients also have obesity. The trial will be a direct competitor to SURPASS-2 (Tirzepatide vs Semaglutide). If Retatrutide proves superiority, it will move to first-line in this most frequent clinical situation.

Storage

Lyophilizate (dry powder before reconstitution)

• 2 years at −20 °C (freezer)
• 12 to 18 months at 2 to 8 °C (refrigerator)
• Up to 30 days at room temperature (up to 25 °C), protect from light and moisture

After reconstitution (peptide in solution with bacteriostatic water)

• Up to 28 days at 2 to 8 °C, protected from light
• Clinical formulations of Retatrutide are not yet commercially available, so a direct comparison is missing; we expect a profile similar to Tirzepatide

Practical storage rules

• Let the vial warm to room temperature (15 to 20 min) before opening. A cold vial + warm air = condensation inside the vial, which disrupts the peptide.
• Do not freeze after reconstitution — Retatrutide is especially sensitive to freezing due to the fatty diacid on the molecule, which can aggregate during freezing. Similar to Tirzepatide.
• Darkness is your friend — UV light progressively degrades the peptide, especially via oxidation of tryptophan and methionine residues.
• Do not shake! Mechanical stress can cause aggregation of the albumin-binding portion of the molecule. Retatrutide has critical conformational requirements due to simultaneous binding to three different receptors — any mechanical stress can disrupt the shape of the molecule.
• The solution should remain clear. Any cloudiness or aggregates mean the molecule is breaking down — the peptide is no longer functionally active.

Reconstitution

3-step visual

1. Reconstitute — add bacteriostatic water down the wall of the vial
2. Measure — use the calculator (Section 8) to compute the required volume
3. Store — refrigerator 2 to 8 °C, protect from light

Detailed protocol

What you will need:

• Retatrutide vial (5 mg lyophilizate)
• 2 to 3 mL bacteriostatic water (contains 0.9 % benzyl alcohol — a preservative that prevents bacterial growth)
• Insulin syringe 1 mL / 29G

Procedure:

1. Let the Retatrutide vial reach room temperature (15 to 20 min). A cold vial + warm water = condensation that disrupts peptide stability.
2. Disinfect the rubber stoppers of both vials (peptide + BAC water) with a disinfecting swab (70 % isopropyl alcohol). Let the alcohol evaporate.
3. Draw the required volume of BAC water with the insulin syringe. The standard for a 5 mg vial is 2.5 mL → resulting concentration 2 mg/mL = 2000 µg/mL.
4. Inject the water slowly down the wall of the vial. Never directly onto the lyophilizate — a strong jet can denature the peptide.
5. Let the vial rest for 3 to 5 minutes. Retatrutide has the most complex molecule of all the incretin peptides, combining motifs from three hormones. Dissolution may take slightly longer than for Semaglutide or Tirzepatide.
6. Gently swirl the vial in circular motions (NEVER shake!) for 90 to 120 seconds until all the powder dissolves. The solution should be completely clear — no cloudiness, no floating particles.
7. Store in the refrigerator at 2 to 8 °C, protected from light.

Alternative volumes for different final concentrations

Rule of thumb: For Retatrutide we recommend 2.5 mL volume as the optimal compromise between concentration and measurement accuracy. At a 12 mg target dose and 2 mg/mL concentration, the volume is 6 mL — exceeding a 1 mL insulin syringe — so for higher doses we recommend 1 mL volume (5 mg/mL concentration → 12 mg dose = 2.4 mL).

Stacking tips — Frequently combined peptides

In the research literature and the community around metabolic peptides, Retatrutide is combined with several molecules for specific goals.

Semaglutide or Tirzepatide — alternative metabolic peptides

For research that compares triple agonism with a GLP-1 mono-agonist or a dual agonist, Semaglutide and Tirzepatide are direct comparators. They are not combined simultaneously — they are mutually exclusive alternatives within a single protocol. Combining Retatrutide + Tirzepatide would lead to duplicate GLP-1R/GIPR activation without additive benefit.

AOD-9604 — complementary lipolytic profile

AOD-9604 is a modified hGH fragment with a clean lipolytic effect without influence on insulin or IGF-1. In research it is combined with Retatrutide to separate the thermogenic effect (Retatrutide’s glucagon component) from direct lipolysis (AOD-9604). For Retatrutide this is less important than for Semaglutide, because glucagon already strongly activates lipolysis on its own.

MOTS-c — mitochondrial support

Retatrutide produces the strongest metabolic switch of all incretin peptides — the thermogenic effect means mitochondria are working at higher gear. MOTS-c is a mitochondrial peptide that improves the efficiency of the mitochondrial OXPHOS pathway. In a hypothetical research context, MOTS-c could support mitochondrial capacity during increased energy expenditure.

BPC-157 and TB-500 — against muscle catabolism

With Retatrutide, the concern about muscle mass loss is proportionally highest among all incretin peptides — at stronger weight reduction (up to −24 %) the risk of sarcopenia is greatest. Research protocols explore whether regenerative peptides (BPC-157, TB-500) combined with resistance training can mitigate this effect. This is especially relevant for Retatrutide.

Ipamorelin + CJC-1295 — anabolic counterweight

For the same reason (muscle catabolism during rapid reduction), the literature describes combinations with a GH stack — anabolic signaling pathways in opposition to the catabolic pressure of caloric deficit. With Retatrutide the need is even more pronounced than with Tirzepatide or Semaglutide.

FAQ — Frequently asked questions

What is Retatrutide and how does it differ from Semaglutide and Tirzepatide? Retatrutide is a triple agonist of the GIP + GLP-1 + glucagon receptor. Semaglutide activates only GLP-1; Tirzepatide activates GIP + GLP-1. The glucagon component adds something no other incretin peptide has — increased energy expenditure (thermogenesis) via the liver and brown adipose tissue. Result: one of the largest body-weight reductions reported in published incretin Phase 2 data to date (−24.2 % in Phase 2).

Is Retatrutide approved? Not yet. Retatrutide is in Phase 3 clinical trials (the TRIUMPH program). FDA approval is expected at the earliest 2026 to 2027 for obesity, similarly for T2DM. The commercial name has not yet been revealed. Molequa supplies the pure form for research purposes — for laboratory research and replication of Phase 2 protocols.

Why wouldn’t glucagon be bad? It raises blood glucose. Classic glucagon at full concentration — yes, which is why it is used to treat hypoglycemia. But Retatrutide has a precisely tuned ratio of receptor activity (GIPR : GLP-1R : GCGR ≈ 1 : 0.3 : 0.7). The insulinotropic component via GIP and GLP-1 outweighs the glucagon effect. The Phase 2 result: HbA1c drop of 1.4 to 2.0 percentage points, without hyperglycemia.

What is the recommended dosing in Phase 2 studies?

• Phase 2 obesity: titration 1 → 2 → 4 → 6 → 8 → 12 mg/week, escalation every 2 weeks
• Phase 2 T2DM: same titration profile, maximum doses 8 to 12 mg/week

Titration is key — a slow increase minimizes GI adverse effects, which are somewhat more intense with Retatrutide than with Tirzepatide because of the glucagon component.

Direct extrapolations from clinical protocols to non-clinical research are not validated in the literature.

What is Retatrutide’s half-life? ~6 days (140 to 150 hours). Between Semaglutide (7 days) and Tirzepatide (5 days). The half-life is achieved via albumin binding (C20 fatty diacid on the lysine) + DPP-IV resistance (Aib at position 2).

Does Retatrutide work orally? No. No oral formulation of Retatrutide is in development. The large molecule (39 aa) and complex structure make oral absorption impractical. Eli Lilly is developing orforglipron (a non-peptide oral GLP-1 agonist), but that is not a Retatrutide analogue.

Are adverse effects known? Yes, from the Phase 1b and Phase 2 trials:

Common (>10 %): nausea, vomiting, diarrhea, constipation, reduced appetite (desired effect), abdominal pain — especially during titration. With Retatrutide somewhat more frequent than with Tirzepatide based on Phase 2 data.

Specific to Retatrutide:

• Mild increase in pulse rate by 5 to 10 BPM (probably via the glucagon effect)
• Hair shedding (telogenic) — more frequent than with Semaglutide or Tirzepatide, but reversible after weight stabilization
• Mild elevation of liver enzymes in the first 4 to 8 weeks (paradoxically, the long-term effect is a drop in ALT/AST)

Rare but serious (from preclinical data and Phase 1/2):

• Pancreatitis — not yet confirmed, signal not monitored
• Cholelithiasis — presumed profile similar to other incretin peptides
• Muscle mass loss — proportionally highest with rapid reduction

Who should NOT take Retatrutide (within clinical trials)? In Phase 3 protocols the exclusion criteria are:

• Personal or family history of medullary thyroid carcinoma
• MEN-2 syndrome
• Pregnancy and lactation
• Type 1 diabetes
• Severe retinopathy
• History of pancreatitis
• Severe hepatic impairment (Child-Pugh C)

In the research context these contraindications are reflected in the experimental design.

How fast does the effect kick in?

• Glycemic effect: onset within days, full stabilization 4 to 6 weeks (similar to Semaglutide)
• Weight effect: first signs 1 to 2 weeks (the fastest of all incretin peptides, thanks to the thermogenic component), full effect 48 to 72 weeks
• Plasma steady-state: 4 weeks with weekly dosing

What is the “glucagon paradox”? Classic glucagon raises glycemia, which is why it is used to treat hypoglycemia. Retatrutide as a glucagon receptor agonist paradoxically does not worsen glycemic control. The reason: the GIP and GLP-1 components stimulate insulin strongly enough to compensate for the hepatic glucose output induced by the glucagon signal. The net effect is glycemia reduction, not increase. This paradox was the main concern of regulators, which the Phase 1b/2 trials have so far resolved.

Does Retatrutide cause hypoglycemia? On its own, NO — all three receptor pathways (GIPR, GLP-1R, GCGR) are predominantly glucose-dependent in the context of normal glycemia. Yes, when combined with sulfonylureas or insulin — then hypoglycemia is a real risk.

What is the WADA status? Retatrutide was added to the WADA Prohibited List in 2024 in category S2 (Peptide Hormones, Growth Factors, Related Substances) as part of the incretin family. Banned for professional athletes including out-of-competition. WADA has a developed LC-MS/MS detection method.

Why is Molequa Retatrutide the most expensive of all the metabolic peptides? Four reasons:

1. The most complex synthesis — 39 amino acids with precise substitutions for triple-receptor selectivity
2. The highest purity requirements — requires extended HPLC purifications and MS/MS verification
3. Limited global capacity — there are no established wholesale supply chains as there are for Semaglutide
4. Premium price positioning in the pre-registration window — Eli Lilly has not yet released price pressure

Will Retatrutide be stronger than Tirzepatide in Phase 3? Probably yes, but it is an open question. In Phase 2, Retatrutide achieved −24.2 % vs Tirzepatide −22.5 % in SURMOUNT-1. But Phase 2 results are often somewhat higher than Phase 3 (the effect of smaller, selected populations). A definitive comparison will come with a head-to-head Phase 3 study, which has not yet been launched.

What is the purity of this batch? The current batch 2026-04-F: ≥ 99.0 % HPLC. The full CoA with HPLC chromatogram, MS spectrum (confirmation MW 4 731.55 Da) and related-impurities profile is available for download or upon request. For Retatrutide we apply an extended MS/MS fragmentation analysis due to structural similarity with Tirzepatide and Survodutide.